Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Two-step personalized immunotherapy safe for patients with ovarian cancer

Most ovarian cancer patients are diagnosed with late stage disease that is unresponsive to existing therapies. In a new study, researchers from the Perelman School of Medicine at the University of Pennsylvania School of Medicine show that a two-step personalized immunotherapy treatment - a dendritic cell vaccine using patients' own tumor followed by adoptive T cell therapy - triggers anti-tumor immune responses in these type of patients.

1 Feb 2013

Merck full-year 2012 worldwide sales decrease 2% to $47.3 billion

Merck, known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2012.

1 Feb 2013

University of Leicester's GENIE to host Lifestyle and Cancer Awareness Workshop on Feb. 23

Women with a family history of breast or ovarian cancer are invited to meet with experts who will advise on preventing or delaying the disease. The University of Leicester's Genetics Education Networking for Innovation and Excellence (GENIE) will hold its third Lifestyle and Cancer Awareness Workshop on Saturday, February 23.

1 Feb 2013

DSMB recommends continuation of CTI’s OPAXIO Phase 3 trial on ovarian cancer

Cell Therapeutics, Inc. (CTI) today announced that the Gynecologic Oncology Group (GOG) informed CTI that an independent Data Safety Monitoring Board (DSMB) recommended continuation of the GOG-0212 Phase 3 clinical trial of OPAXIOTM (paclitaxel poliglumex) as maintenance therapy in ovarian cancer with no changes following a planned interim survival analysis.

31 Jan 2013

ADRB receptors play a direct role in Src activation by PKA-mediated mechanism

Scientists at The University of Texas MD Anderson Cancer Center have discovered the signaling pathway whereby a master regulator of cancer cell proteins - known as Src - leads to ovarian cancer progression when exposed to stress hormones. The researchers report in the current issue of Nature Communications that beta blocker drugs mitigate this effect and reduce cancer deaths by an average of 17 percent.

30 Jan 2013

FDA allows IND application for ImmunoCellular’s ICT-140 to treat ovarian cancer

ImmunoCellular Therapeutics, Ltd. announced that the US Food and Drug Administration (FDA) has allowed the investigational new drug (IND) application for ICT-140, paving the way for conducting a clinical trial.

30 Jan 2013

KLF8 protein could be helpful in preventing cancer recurrence

Just as the body can become resistant to antibiotics, certain methods of killing cancer tumors can end up creating resistant tumor cells. But a University of Central Florida professor has found a protein present in several types of cancer, including breast and ovarian cancer, which could be helpful in preventing tumors from coming back.

29 Jan 2013

Women with BRCA gene mutations tend to undergo menopause sooner than others

Women with harmful mutations in the BRCA gene, which put them at higher risk of developing breast and ovarian cancer, tend to undergo menopause significantly sooner than other women, allowing them an even briefer reproductive window and possibly a higher risk of infertility, according to a study led by researchers at UC San Francisco.

29 Jan 2013

High blood calcium levels may predict ovarian cancer

A new study from Wake Forest Baptist Medical Center is the first to report that high blood calcium levels might predict of ovarian cancer, the most fatal of the gynecologic cancers.

25 Jan 2013

Study examines associations between blood calcium and ovarian cancer

A new study from Wake Forest Baptist Medical Center is the first to report that high blood calcium levels might predict ovarian cancer, the most fatal of the gynecologic cancers.

24 Jan 2013

World Cancer Day to focus on awareness and prevention, importance of research

Cancer takes the lives of some 7.6 million people worldwide each year, according to the World Health Organization. And while the upcoming World Cancer Day will focus on a global message of cancer awareness and prevention, the importance of cancer research also will resonate.

23 Jan 2013

SLU team discovers molecular pathway that contributes to triple-negative breast cancer

In research published in the Jan. 17 issue of The Journal of Cell Biology, a team led by Susana Gonzalo, Ph.D., assistant professor of biochemistry and molecular biology at Saint Louis University, has discovered a molecular pathway that contributes to triple-negative breast cancer, an often deadly and treatment resistant form of cancer that tends to strike younger women.

23 Jan 2013

Bevacizumab QoL impact highlighted in ovarian cancer patients

The ICON7 study results suggest that improved progression-free survival with bevacizumab therapy for high-risk ovarian cancer may come at the cost of health-related quality of life.

21 Jan 2013

Boehringer Ingelheim receives FDA Priority Review for afatinib to treat EGFR mutation-positive NSCLC

Boehringer Ingelheim today announced that the New Drug Application (NDA) for its investigational oncology compound afatinib has been accepted for filing and granted Priority Review by the U.S. Food and Drug Administration (FDA).

17 Jan 2013

New method based on mass sequencing can detect hereditary breast and ovarian cancer syndrome

Researchers of the Catalan Institute of Oncology (ICO) at the Bellvitge Biomedical Research Institute (IDIBELL) have developed and validated a new method to diagnose hereditary breast and ovarian cancer syndrome based on mass sequencing of BRCA1 and BRCA2 genes. The model is based on a genetic and bioinformatic analysis which has been proved very effective.

17 Jan 2013

‘PapGene’ test detects endometrial and ovarian cancers

Researchers have adapted the papanicolaou smear test currently used to detect cervical cancer so that it can be used to screen women for endometrial and ovarian cancers.

14 Jan 2013

Cancer researchers solve mystery of how Chd5 protein exerts its beneficial effects

A team of cancer researchers at Cold Spring Harbor Laboratory (CSHL) has solved the mystery of how one of the most powerful of the body's natural tumor-suppressing proteins, called Chd5, exerts its beneficial effects.

11 Jan 2013

Results from Morphotek’s farletuzumab Phase III combination study on ovarian cancer

Morphotek Inc., a wholly-owned subsidiary of Eisai Inc., announced today top-line results from a Phase III study of its investigational agent farletuzumab (MORAb-003) in combination with carboplatin and a taxane in patients with platinum-sensitive epithelial ovarian cancer in first relapse.

11 Jan 2013

Johns Hopkins develops PapGene test to diagnose ovarian and endometrial cancers

Using cervical fluid obtained during routine Pap tests, scientists at the Johns Hopkins Kimmel Cancer Center have developed a test to detect ovarian and endometrial cancers. In a pilot study, the "PapGene" test, which relies on genomic sequencing of cancer-specific mutations, accurately detected all 24 (100 percent) endometrial cancers and nine of 22 (41 percent) ovarian cancers. Results of the experiments are published in the Jan. 9 issue of the journal Science Translational Medicine.

11 Jan 2013

Key link between stem cell factors that fuel ovarian cancer's growth and patient prognosis

Researchers at Yale School of Medicine have identified a key link between stem cell factors that fuel ovarian cancer's growth and patient prognosis. The study, which paves the way for developing novel targeted ovarian cancer therapies, is published online in the current issue of Cell Cycle.

9 Jan 2013